Dapagliflozin Effective in T2D with HFrEF Regardless of Type of Background T2D Therapy

In the DAPA-HF trial, the SGLT-2 inhibitor dapagliflozin improved clinical outcomes in patients wtih heart failure with reduced ejection fraction, with or without type 2 diabetes (T2D). Kieran Docherty, MBChB, discusses results of an important DAPA-HF subanalysis that found dapagliflozin benefits are not affected by background T2D therapy or the type of therapy. Results were presented at the recent 2020 American Diabetes Association Scientific Sessions.